



## MRD Report

### PATIENT

Name: Sample Patient  
DOB: 1943-05-01  
Age & Gender: 79, Male  
MRN: GW0117  
Collection Date: 2022-07-03  
Received Date: 2022-07-05  
Report Date: 2022-07-18

### PHYSICIAN


Name: Sample Physician  
Account: Sample Clinic  
Practice Name: Sample Clinic  
Phone: (415) 555-0250  
Fax: (415) 555-0255  
Address: 123 Genomics Blvd., Diagnostics, CA 94127

### Recurrence Risk

# NEGATIVE

## Low Recurrence Risk

### Genomic Disease Burden Monitor disease response over time



Patient is in the **4th percentile** for disease burden, meaning that 4% of bladder cancer surveillance patients tested with UroAmp had less disease burden, and 96% had more disease burden.

### UroAmp Prognostic Insights

- UroAmp test results are consistent with response to nadofaragene.
- Compared to earlier testing on 02.27.22 and 11.06.22, mutations associated with invasive cancers are no longer detected.